Baird Medical stock hits a record low, with a year-to-date decline of over 40%

The stock price of Bayerd Medical (BDMD.OQ) has shown a significant decline over the past 7 days (February 7 to February 13, 2026), attracting market attention. According to internal databases and public information, the key market data are as follows:

February 12, 2026: Closing price $0.80, down 4.76% for the day, with an intraday low of $0.77, hitting a new all-time low. The volatility was 12.47%, with a trading volume of only $85,200 and a turnover rate of 0.28%. Since the beginning of the year, the total decline has expanded to 41.17%.

February 11, 2026: Closing price $0.84, down 7.59% for the day, opening at $0.95, with a low of $0.80. The volatility was 16.51%, and the trading volume was $200,600. The Economic Observer reported that the stock price fell 8.69% (closing at $0.83) that day. The company did not release any major negative announcements, but the trailing twelve months (TTM) P/E ratio was negative (-7.55), indicating ongoing losses, and liquidity was low (trading volume about $179,500), making small sell orders prone to large fluctuations.

February 10, 2026: Closing price $0.91, down 10.00% for the day, with a trading volume of $149,000.

February 9, 2026: Closing price $1.01, up 9.78% for the day, with a trading volume of $117,200, marking the only recent day of gains.

Over the past 7 days (based on trading days with data), the stock price has fallen by 13.04% (from a baseline of $0.92 before February 9 to $0.80 on February 12), with a volatility of 31.30%. During the same period, the U.S. healthcare equipment sector declined slightly by 0.41%, and the Nasdaq index fell by 2.03%, indicating that the individual stock’s performance diverges from the industry and broader market, possibly due to weak company fundamentals and lack of market confidence.

Recent Events

On February 11, 2026, Bayerd Medical’s stock hit a new all-time low, dropping over 8% in a single day. The Economic Observer reported that this decline was not accompanied by any major company announcements, but since the start of the year, the stock has fallen by 38.96%, highlighting investor concerns over ongoing losses. In the industry context, the medical devices sector rose slightly by 0.07%, while the Nasdaq declined by 0.04%, with Bayerd Medical performing significantly worse than its peers, possibly reflecting specific risks.

The above information is compiled from public sources and does not constitute investment advice.